CMPX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CMPX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Compass Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $148.54 Mil. Compass Therapeutics's Total Assets for the quarter that ended in Dec. 2023 was $156.88 Mil.
The historical rank and industry rank for Compass Therapeutics's Equity-to-Asset or its related term are showing as below:
During the past 6 years, the highest Equity to Asset Ratio of Compass Therapeutics was 0.95. The lowest was -3.90. And the median was 0.84.
The historical data trend for Compass Therapeutics's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Compass Therapeutics Annual Data | |||||||||||||||
Trend | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Equity-to-Asset | Get a 7-Day Free Trial | -3.90 | 0.77 | 0.91 | 0.91 | 0.95 |
Compass Therapeutics Quarterly Data | ||||||||||||||||||||
Dec18 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Equity-to-Asset | Get a 7-Day Free Trial | 0.91 | 0.93 | 0.94 | 0.94 | 0.95 |
For the Biotechnology subindustry, Compass Therapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Compass Therapeutics's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Compass Therapeutics's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Compass Therapeutics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as
Equity to Asset (A: Dec. 2023 ) | = | Total Stockholders Equity | / | Total Assets |
= | 148.538 | / | 156.875 | |
= |
Compass Therapeutics's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as
Equity to Asset (Q: Dec. 2023 ) | = | Total Stockholders Equity | / | Total Assets |
= | 148.538 | / | 156.875 | |
= |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Compass Therapeutics (NAS:CMPX) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Thank you for viewing the detailed overview of Compass Therapeutics's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Richard S Lindahl | director | NEXTEL, 2001 EDMUND HALLEY DR, RESTON VA 20191 |
Thomas J. Schuetz | director, officer: Chief Executive Officer | C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063 |
David M Wurzer | director | C/O CURAGEN CORP, 555 LONG WHARF DR. 11TH FL., NEW HAVEN CT 06511 |
Vered Bisker-leib | officer: Chief Operating Officer | C/O COMPASS, 245 FIRST STREET, 3RD FLOOR, CAMBRIDGE MA 02142 |
Orbimed Advisors Llc | director, 10 percent owner | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
Carl L Gordon | director, 10 percent owner | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
James P Boylan | director | C/O ENAVATE SCIENCES, 2884 SAND HILL RD., STE 100, MENLO PARK CA 94025 |
Ellen Chiniara | director | 51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453 |
Mary Ann Gray | director | 201 W 70TH ST, SUITE 23K, NEW YORK NY 10023 |
Philip Ferneau | director | 10 ALLEN STREET, HANOVER NH 03755 |
Orbimed Capital Gp V Llc | director, 10 percent owner | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
Orbimed Genesis Gp Llc | director, 10 percent owner | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
Miranda Jayne Toledano | director | C/O COMPASS THERAPEUTICS, INC., 80 GUEST STREET, SUITE 601, BOSTON MA 02135 |
Susan Kalled | officer: Chief Scientific Officer | COMPASS THERAPEUTICS, INC., 80 GUEST ST., SUITE 601, BOSTON MA 02135 |
Brett Kaplan | director | C/O PREVAIL THERAPEUTICS INC., 430 EAST 29TH STREET, SUITE 940, NEW YORK NY 10016 |
From GuruFocus
By GuruFocus Research • 11-09-2023
By Value_Insider Value_Insider • 12-15-2022
By sperokesalga sperokesalga • 05-04-2023
By Value_Insider Value_Insider • 11-22-2022
By Value_Insider Value_Insider • 12-01-2022
By Marketwired • 11-07-2023
By Stock market mentor Stock market mentor • 02-02-2023
By GuruFocusNews GuruFocusNews • 06-30-2022
By Marketwired • 08-30-2023
By Value_Insider Value_Insider • 11-09-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.